Literature DB >> 32356140

Differences in cancer survival by remoteness of residence: an analysis of data from a population-based cancer registry.

Nina Afshar1,2, Dallas R English3,4, James A Chamberlain3, Tony Blakely4, Vicky Thursfield5, Helen Farrugia5, Graham G Giles3,4,6, Roger L Milne3,4,6.   

Abstract

PURPOSE: Cancer survival is generally lower for rural compared with urban residents, but findings have been inconsistent. We aimed to assess inequalities in cancer survival by remoteness of residence in Victoria, Australia.
METHODS: Incident cancer cases diagnosed in 2001-2015 with 30 cancer types (n = 331,302) were identified through the Victorian Cancer Registry and followed to the end of 2015 through death registries. Five-year net survival was estimated using the Pohar-Perme method and differences assessed by excess mortality rate ratios (EMRRs) using Poisson regression, adjusting for sex, age and year of diagnosis. EMRRs adjusted for socio-economic disadvantage were also estimated.
RESULTS: People living outside major cities had lower survival for 11 cancers: esophagus, stomach, colorectum, liver, gallbladder/biliary tract, pancreas, lung, connective/soft tissue, ovary, prostate, kidney. No differences in survival were found for cancers of uterus, small intestine and mesothelioma. After adjusting for socio-economic disadvantage, the observed differences in survival decreased for most cancers and disappeared for colorectal cancer, but they remained largely unchanged for cancers of esophagus, stomach, liver, pancreas, lung, connective/soft tissue, ovary and kidney.
CONCLUSION: People with cancer residing outside major cities had lower survival from some cancers, which is partly due to the greater socio-economic disadvantage of rural residents.

Entities:  

Keywords:  Cancer survival; Excess mortality; Inequalities; Rural; Survival analysis; Urban

Year:  2020        PMID: 32356140     DOI: 10.1007/s10552-020-01303-2

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  3 in total

1.  Cancer survival differentials for Aboriginal and Torres Strait Islander peoples in Queensland: the impact of remoteness.

Authors:  S M Cramb; L J Whop; G Garvey; P D Baade
Journal:  Cancer Causes Control       Date:  2022-10-20       Impact factor: 2.532

2.  Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients.

Authors:  Mitsuru Sugimoto; Tadayuki Takagi; Rei Suzuki; Naoki Konno; Hiroyuki Asama; Yuki Sato; Hiroki Irie; Yoshinori Okubo; Jun Nakamura; Mika Takasumi; Minami Hashimoto; Tsunetaka Kato; Ryoichiro Kobashi; Takuto Hikichi; Hiromasa Ohira
Journal:  BMC Cancer       Date:  2021-12-09       Impact factor: 4.430

Review 3.  Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer.

Authors:  Mitsuru Sugimoto; Tadayuki Takagi; Rei Suzuki; Naoki Konno; Hiroyuki Asama; Yuki Sato; Hiroki Irie; Yoshinori Okubo; Jun Nakamura; Mika Takasumi; Minami Hashimoto; Tsunetaka Kato; Ryoichiro Kobashi; Takuto Hikichi; Hiromasa Ohira
Journal:  Fukushima J Med Sci       Date:  2022-02-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.